Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenanceMaría‐Victoria Mateos, Jesús F. San Miguel, María-Ángeles Montalbán et al.|Blood|2011Cited by 58
A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years.María‐Victoria Mateos, Jesús F. San Miguel, Albert Oriol et al.|Blood|2009Cited by 45